How much will the medical insurance price of Eltrombopag be newly adjusted in 2025?

Eltrombopag is a thrombopoietin receptor agonist, mainly used to treat chronic immune thrombocytopenia (ITP), hepatitis C-related thrombocytopenia, severe aplastic anemia and other diseases. With its widespread clinical application, eltrombopag has been officially launched in my country and has been included in the national medical insurance directory. After the latest adjustment to the medical insurance policy in 2025, the drug’s reimbursement ratio and applicable population will be further optimized, allowing more patients to obtain treatment at lower out-of-pocket costs.

According to the latest price information, the current overall price of Eltrombopag sold in China remains between one or two thousand yuan to four or five thousand yuan. The specific price varies depending on the brand, specifications and hospital procurement channels. After medical insurance reimbursement, the patient's out-of-pocket expenses are significantly reduced. For example, after some provinces and cities reimburse 50 mg eltrombopag, the out-of-pocket price may be controlled at around one to two thousand yuan, significantly reducing the financial burden on patients. This price adjustment is important for chronic ITP patients who take long-term medication.

In addition to the domestic original drug, the original drug Eltrombopag produced by Novartis in India is also a common imported version on the market, with specifications of 25mg14 tablets and 50mg14 tablets. The latest market quotation in 2025 shows that the price of 25mg specification is about 1700 yuan, while the price of 50mg specification is less than 3000 yuan. These original drugs are consistent with the domestically sold versions in terms of ingredients, efficacy and quality, and are the first choice for many patients purchasing drugs overseas. In addition, there are also generic versions of Eltrombopag produced in many countries, such as Laos, India and Bangladesh. The ingredients are basically the same and the price is more affordable, usually several hundred yuan per box, making it suitable for patients with greater financial pressure.

In summary, 2025 adjustments to the medical insurance policy have made the actual cost of eltrombopag more controllable. Patients can choose a suitable version of the drug based on their condition and financial situation. Whether it is a domestic original drug covered by medical insurance or an overseas original or generic drug with reliable quality, it provides diversified treatment options for ITP and other patients. It is recommended that patients use it under the guidance of a doctor and pay attention to the specific implementation details of the medical insurance policy to obtain maximum medication and economic benefits.

Reference materials:https://go.drugbank.com/drugs/DB06210